Illumina appointed former NHGRI director Eric Green as chief medical officer, a hire the company said will accelerate its push into clinical genomics and precision medicine. Interviews and coverage appeared in GenomeWeb and STAT. Green—long associated with genomic policy and clinical translation—will advise Illumina on clinical adoption, regulatory strategy and product positioning as the firm expands multiomics and clinical sequencing offerings. Illumina and hospital collaborators also announced regional CGP initiatives, reinforcing the clinical pivot. The move signals Illumina’s intent to prioritize clinical-market leadership and to bolster relationships with health systems, payers and regulators as genomic testing moves deeper into standard care pathways.